University of Texas, Arlington NURS 5334; Endocrine Prescribing Case| Complete Grade Sheet/Rubric for Pharmacology Case Studies 2026 update

This rubric is used in the practice and graded prescription cases. You can write [if it is legible] or type into the table. No credit is given for work that is not on this document. Cite references [from required reference in the course such as texts, Epocrates] to generate your answers in the body of the work. References should cite pages from the text that you used or URL from Epocrates. For each drug that you prescribe, fill in the required elements of this table and then the 1-page prescription. Grading faculty will not view text that exceeds 2 pages. Part 3 and the prescription on the last page do not count toward the 2-page limit. Make sure to include your name where it says student name below this paragraph. Student Name: Part One [25 points] Instructions Points • Cite the drug and drug class that is the best choice for this patient at this time: Glucagon-like peptide-1 (GLP-1) X/15 • Cite the name of the medicine you will prescribe and its MOA: Rybelsus (semaglutide) activates glucagon-like-peptide-1 (GLP-1) receptor, increasing insulin secretion, decreasing glucagon secretion, and delaying gastric emptying (incretin mimetic) X/9 • If there was data from the patient’s history or exam that was relevant to choosing this agent, cite those here: - Patient A1C is 8.9% and fasting blood sugar is 150 Mg/dl with postprandial blood glucose reading of 210-235. Rybelsus is highly effective at lowering both fasting sugars, which could help bring her A1C closer to target. - The patient is obese and Rybelsus promotes significant weight loss, given that she has PCO weight loss will be beneficial for managing her diabetes ans PCO symptoms. - Patient is hypertensive even when she is taking bp medication. Rybelsus has proven to have cardiovascular benefits, reducing the risk of heart attack, stroke and other cardiac events. X/1 Part Two [35 points] Instructions Points • Labs/Diagnostics needed before starting this drug? Any ongoing lab monitoring or diagnostics need while the patient is on this medication? Before starting and ongoing labs are A1C before to establish baseline and ongoing to efficacy of treatment and adjusted if needed. GFR lab to monitor proteinuria to see if it worsens or if there is any sign of declining renal function. Thyroid function before and ongoing to check any abnormalities, also GLP-1 receptors agonists have been linked to medullary thyroid carcinoma. X/2 • Black Box Warning for this Medication? Thyroid C-cell Tumor Risk contraindicated in pts w/ medullary thyroid carcinoma (MTC) hx or family hx, or in pts w/ multiple endocrine neoplasia syndrome type 2 (MEN 2); dose-related and duration-dependent incr. in thyroid C-cell tumor incidence observed in rodents, but human relevance unknown; uncertain value of routine serum calcitonin or thyroid ultrasound monitoring; advise pts of potential MTC risk and thyroid tumor sx (e.g., neck mass, dysphagia, dyspnea, persistent hoarseness) X/3 • Contraindications? X/2 1 Instructions Points hypersensitivity to drug or ingredient, breastfeeding, medullary thyroid CA hx medullary thyroid CA family hx ,multiple endocrine neoplasia syndrome type 2 ,diabetes mellitus, type 1, caution: hypersensitivity to GLP-1 agonists, caution: renal impairment ,caution: volume depletion, caution: pancreatitis risk, caution: pancreatitis hx , caution: diabetic retinopathy, caution: female pts of reproductive potential • ADEs Thyroid C-cell tumor (animal studies), medullary thyroid CA risk, papillary thyroid CA, hypersensitivity rxn, anaphylaxis, angioedema, acute renal failure, chronic, renal failure exacerbation, pancreatitis, cholelithiasis, cholecystitis, ileus X/10 • Common Side Effects Nausea, Stomach (abdominal) pain, Diarrhea, Decreased appetite, Vomiting, Constipation inflammation of your pancreas (pancreatitis). changes in vision. low blood sugar (hypoglycemia). kidney problems (kidney failure). In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems to get worse. It is important for you to drink fluids to help reduce your chance of dehydration X/10 • Specific education/counseling that should be done for this patient at this time?